Brief: Uniqure Provides Regulatory Update On Amt-130 For Huntington’S Disease
04/12/2025 14:08
Dec 4 (Reuters) - UNIQURE PROVIDES REGULATORY UPDATE ON AMT-130 FOR HUNTINGTON’S DISEASE UNIQURE NV - FDA SAYS AMT-130 PHASE I/II DATA UNLIKELY TO SUPPORT BLA SUBMISSION UNIQURE NV: EVALUATING FEEDBACK AND PLANS TO URGENTLY REQUEST A FOLLOW-UP MEETING WITH FDA TO TAKE PLACE IN Q1 OF 2026 Source text: ID:nGNX4bfD07 ((Reuters.Briefs@thomsonreuters.com;))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal